Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

RCON, URRE, SRLS, MJS.V, PWRM Stock Market Report from


Stock-PR Reporting



FREE Daily Stock Alerts From



Majestic Gold Corp. (TSX.V:MJS) recently announced results of mining operations at Song Jiagou for the first three calendar quarters of 2010:

*Total of 4,709.37 ounces of gold produced and 4,592.13 ounces of gold sold for the period; the balance remains in inventory

*Gold sales of US $5,419,422 for the period at an average price of US $1,180.15 per ounce

*Steady increase in head grades quarter over quarter (11.1% increase)

*Average price per gold ounce of US $1,246.92 during the third calendar quarter, slightly above the average spot price for the quarter of US $1,226.62 (source -

*Consistent gold recoveries around 89%

Majestic Gold Corp. is a Vancouver-based; TSX Venture Exchange and Frankfurt Exchange listed gold exploration and development company with a very advanced gold deposit in Shandong province of China. On April 23, 2010, Majestic Gold Corp. released an updated NI 43-101- compliant, indicated and inferred gold resource estimate on its Song Jiagou property.



Power3 Medical Products, Inc. (OTC:PWRM) a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, announced recently that it has signed a definitive agreement to acquire all of the stock of Rozetta-Cell Life Sciences, Inc. Power3 plans to effectuate the acquisition of Rozetta-Cell by merging Rozetta-Cell with and into Power3, with Power3 remaining as the surviving company in the merger. Completion of the merger is subject to customary closing conditions, including receipt by the parties of all necessary board and shareholder approvals and third party consents. There can be no assurance that these conditions will be met or that the merger will be completed.

Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig's disease). Power3 applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 has developed a portfolio of products including BC-SeraPro™, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro®, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer's, Parkinson's and ALS diseases, for which it is currently engaged in Phase II clinical trials. These tests are designed to analyze an individual's proteins to detect the presence of disease, a patient's disease progression, a patient's response to a particular drug, and the mechanisms of disease present in the patient for optimal targeted therapy.


Recon Technology, Ltd. (Nasdaq:RCON) recently announced its financial results for the first fiscal quarter ended September 30, 2010. Summary financial data is provided, First Quarter Fiscal 2011 Financial Highlights. Revenues for the first quarter of fiscal year 2011 decreased by 3.0% year-over-year to $3,254,551, down from $3,354,921 in the first quarter of fiscal 2010.

Recon Technology, Ltd. provides products and services designed to automate and enhance the extraction of petroleum in the People's Republic of China. It engages in the design, manufacture, and installation of oil field servomechanism systems engineering.


Uranium Resources, Inc. (Nasdaq:URRE) recently announced that the United States Supreme Court has denied the opponents’ petition to review the March 2010, 10th Circuit Court of Appeals’ ruling that upheld the Company’s U.S. Nuclear Regulatory Commission license to conduct in-situ recovery uranium mining at the Churchrock/Crownpoint project.

Uranium Resources, Inc. engages in the acquisition, exploration, development, and mining of uranium properties, using the in situ recovery or solution mining process. It owns developed and undeveloped uranium properties in South Texas; and undeveloped uranium properties in New Mexico.


SeraCare Life Sciences, Inc. (Nasdaq:SRLS) will release its fourth quarter and fiscal year 2010 financial results before U.S. financial markets open on Wednesday, December 1, 2010. SeraCare executives will host a conference call at 8:30 A.M. Eastern Time on the same day to review 2010 results and provide an overview of goals and strategic initiatives for fiscal 2011 and beyond.

SeraCare Life Sciences, Inc., a life sciences company, provides products and services to facilitate the discovery, development, and production of human and animal diagnostics, and therapeutics.







Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (OTCPK:CRWE) has received twenty-five thousand dollars in cash from a third party for (thirty) days of advertising for Majestic Gold Corp, TSX Venture Exchange (TSX.V:MJS) and the Frankfurt Stock Exchange (FSE:MJT). Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services from Power 3 Medical Products Inc. (OTC:PWRM).


Sign Up For Free Stock Alerts At


Be Sure To Visit


The views expressed in any article, reports, writings are not necessarily the views of Crown Equity Holdings Inc. its officers, directors, staff, contractors or employees. They do not represent the views or opinions of this site. Views expressed in articles are those of the author alone.